Illumina Ventures — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Pattern develops rapid antibiotic susceptibility and infection diagnostics using single-cell microbiology, which reads the metabolic patterns of individual bacterial cells to deliver ID/AST results in hours without culture steps.
BiotechHealthtechMedical DevicesAustin, US
Nick Arab(Founder & CTO)Ross Johnson(Co-founder & Chief Engineer)inCarey-Ann Burnham(Chief Executive Officer)inTravis Davies(SVP, Operations)inKyle Fieleke(SVP, Corporate Development & Finance)inDavid Bussian(SVP, Clinical, Regulatory & Assay Development)in
Co-investorsAMR Action FundIllumina Innovation
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

